Synthetic pDNA Vaccines for Specialized Environments

Publication ID: 24-11857621_0004_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Synthetic pDNA Vaccines for Specialized Environments,” Published Technical Disclosure No. 24-11857621_0004_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857621_0004_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,621.

Summary of the Inventive Concept

This inventive concept adapts synthetic pDNA vaccines against COVID-19 for specific, high-need environments, including high-security facilities, disaster relief, extreme weather conditions, areas with limited medical infrastructure, and high-altitude environments.

Background and Problem Solved

The original patent disclosed a synthetic pDNA vaccine against COVID-19, but it did not address the unique challenges and requirements of specific environments. This inventive concept solves the problem of inadequate vaccine administration and protection in these environments, ensuring effective vaccination and minimizing risks.

Detailed Description of the Inventive Concept

The inventive concept comprises systems, methods, and kits for administering synthetic pDNA vaccines against COVID-19 in specialized environments. These include secure storage units, controlled environments, portable vaccination units, remote monitoring systems, and supplemental oxygen provision. The inventive concept integrates the original vaccine design with tailored solutions for each environment, ensuring safe and effective vaccination.

Novelty and Inventive Step

The new claims introduce novel combinations of vaccine administration and environmental adaptations, providing a non-obvious solution to the problem of vaccine protection in specialized environments. The inventive concept's unique integration of vaccine design and environmental considerations sets it apart from the original patent.

Alternative Embodiments and Variations

Alternative embodiments may include varying vaccine formulations, adaptable storage and administration systems, and customized training programs for healthcare professionals. Variations may also include integrating the vaccine with existing infrastructure, such as incorporating the vaccine into existing emergency response systems or high-security facilities.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in industries such as biotechnology, healthcare, and emergency response. Target markets include high-security facilities, disaster relief organizations, and areas with limited medical infrastructure. The inventive concept also has potential applications in high-altitude environments, such as mountainous regions or aerospace industries.

CPC Classifications

SectionClassGroup
A A61 A61K39/215
A A61 A61K9/0019
A A61 A61P31/14
C C07 C07K14/005
A A61 A61K2039/53
A A61 A61K2039/54
A A61 A61K2039/545
C C12 C12N2770/20022
C C12 C12N2770/20034
C C12 C12N2770/20071

Field of Art

Biotechnology and vaccine development, specifically synthetic plasmid DNA (pDNA) vaccines for infectious disease prevention, with expertise in molecular biology, immunology, and vaccine formulation techniques

Person of Ordinary Skill (PHOSITA) Profile

A researcher or engineer with advanced degrees in molecular biology or immunology, experienced in vaccine design, genetic engineering, and understanding of environmental adaptation strategies for biological materials

Obviousness Rationale

A person of ordinary skill would recognize that the source patent's pDNA vaccine technology naturally requires consideration of specialized environmental challenges during deployment. The PTD's variations represent predictable engineering solutions that address known limitations in vaccine distribution and administration across diverse contexts. These adaptations follow standard problem-solving approaches in biotechnology by integrating vaccine design with contextual delivery mechanisms.

Obvious Combinations & Variations

Source Patent Element
Synthetic plasmid DNA vaccine targeting SARS-CoV-2 receptor binding domain
PTD Variation
Integrating secure storage units and controlled environments for vaccine administration
Obviousness Reasoning
Predictable solution to vaccine preservation requirements, addressing known temperature and contamination risks in vaccine distribution
Source Patent Element
Genetic sequence for COVID-19 vaccine
PTD Variation
Portable vaccination units with remote monitoring systems for limited infrastructure environments
Obviousness Reasoning
Known technique of adapting medical technologies for resource-constrained settings, utilizing standard telemedicine and portable medical infrastructure approaches
Source Patent Element
Synthetic pDNA vaccine design
PTD Variation
Disaster relief kit with manual for emergency vaccine administration
Obviousness Reasoning
Standard practice of creating deployment protocols and standardized kits for emergency medical interventions, representing a design choice with predictable implementation
Source Patent Element
SARS-CoV-2 vaccine genetic construct
PTD Variation
High-altitude administration protocol with supplemental oxygen provision
Obviousness Reasoning
Routine medical adaptation addressing known physiological challenges, demonstrating standard problem-solving in specialized medical environments
35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. ยง 103, the variations disclosed in this publication would have been obvious to a person having ordinary skill in the art at the time of invention, based on the teachings of US Patent 11857621. The systematic environmental adaptations represent predictable engineering solutions that extend the foundational vaccine technology through routine modifications that would be apparent to a skilled practitioner in biotechnology and vaccine development.

Original Patent Information

Patent NumberUS 11,857,621
TitleSynthetic pDNA vaccines against COVID-19
Assignee(s)Imam Abdulrahman Bin Faisal University